Eli Lilly’s weight loss drug Zepbound was found to reduce obstructive sleep apnea in adults with obesity, the drugmaker said in a release Wednesday. Obstructive sleep apnea affects about 39 ...

Eli Lilly just appointed a corporate officer for ... it's very likely that Fuchs is qualified for the job. He founded an AI company and holds a PhD in machine learning, and he was the dean of ...

Eli Lilly on Wednesday said its weight-loss treatment, Zepbound, was successful in helping patients with obstructive sleep apnea (OSA). A Phase 3 trial found on average Zepbound reduced the number ...

DePauw University students had a unique opportunity on Monday, Sept. 16, 2024, as the global pharmaceutical company Eli Lilly ...

Leerink Partners analyst David Risinger has maintained their bullish stance on LLY stock, giving a Buy rating today. David Risinger’s ...